20 Stocks Insiders Bought in April After Trump’s Tariff Rollout

9. Zymeworks Inc. (NASDAQ:ZYME)

Zymeworks is a clinical-stage biopharmaceutical company that develops cancer treatments, with its lead candidates including zanidatamab, a HER2-targeted therapy in Phases 1-3 of clinical trials, and zanidatamab zovodotin, a Phase 2 antibody-drug conjugate. The company, based in Middletown, Delaware, is also exploring preclinical oncology programs and collaborating with major partners like BeiGene, Celgene, GlaxoSmithKline, and Merck Sharp & Dohme.

In April, one insider bought $3.62 million worth of Zymeworks shares at an average price of $11.51 per share. Year-to-date, the stock is down 27.94% trading at $10.55 per share. Over the past 12 months, Zymeworks returned 9.67%.

For the full year 2024, Zymeworks reported revenue of $76.3 million, slightly up from $76.0 million in 2023. The revenue included $25.0 million in milestone payments from Jazz related to the FDA approval of Ziihera for HER2+ BTC treatment. The company incurred $134.6 million in research and development expenses, down from $143.6 million in 2023, and posted a net loss of $122.7 million, compared to a $118.7 million loss the previous year. As of December 31, Zymeworks held $324.2 million in cash, cash equivalents, and marketable securities.

According to MarketBeat, eight analysts rate Zymeworks stock as a “Moderate Buy” with a price target of $21.00. The average price target suggests an upside of 98.58% from the latest price.